A New York appellate court has upheld a 10-day suspension for thoroughbred horse trainer Todd Pletcher after his horse, Forte, tested positive for a banned substance. The ruling, issued on May 7, 2026, by the Appellate Division of the Supreme Court, confirms the New York State Gaming Commission's decision to penalize Pletcher for violating state regulations regarding drug use in horse racing.

This ruling affects Pletcher, who is a prominent figure in the horse racing industry, and it highlights the strict regulations surrounding medication use in thoroughbred racing. The court's decision reinforces the importance of maintaining a drug-free environment for racehorses, which is crucial for the integrity of the sport.

Background

The case arose after Forte, a thoroughbred trained by Pletcher, won a race at Saratoga Race Course on September 5, 2022. Following the race, blood and urine samples from Forte tested positive for Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) that is not permitted for use in racing horses in New York. The New York State Gaming Commission issued a notice to Pletcher, suspending his license for 10 days and imposing a fine of $1,000.

Pletcher appealed the decision, arguing that the interpretation of the regulations was not rational. The case was transferred to the appellate court after the Supreme Court denied the Gaming Commission's motion to dismiss the petition. The central issue was whether the commission could determine a violation based solely on the positive test results for Meloxicam, without direct evidence of when the drug was administered.

The Ruling

The appellate court ruled in favor of the New York State Gaming Commission, affirming the suspension and fine imposed on Pletcher. The judges concluded that the presence of Meloxicam in Forte's postrace samples constituted substantial evidence of a violation of the regulations. The court stated, "It is rational for respondent to find that a postrace positive test for Meloxicam, in and of itself, constitutes substantial evidence of a violation of 9 NYCRR 4043.2 (d) without the need for direct proof that Meloxicam was administered within the seven days of the race."

The judges emphasized that the regulatory framework aims to ensure the safety of horses and fairness in racing. They noted that the interpretation of the rules by the Gaming Commission was not irrational or unreasonable, as it aligns with the overall goals of maintaining a drug-free environment in horse racing.

Impact

This ruling sets a significant precedent for the horse racing industry in New York, reinforcing the strict enforcement of drug regulations. It serves as a reminder to trainers and owners about the importance of compliance with medication rules to avoid penalties. The decision also highlights the challenges of proving when certain substances were administered, as the court found that the presence of Meloxicam alone was sufficient to establish a violation.

The ruling may influence future cases involving drug testing in horse racing, as it clarifies the standards for proving violations under the state's regulations. It underscores the responsibility of trainers to ensure their horses are not exposed to prohibited substances, as the burden of proof shifts to them once a positive test is confirmed.

What's Next

Pletcher may seek to appeal the ruling to a higher court, although details on any potential appeal were not provided in the court filing. The outcome of this case could have implications for other trainers facing similar allegations in the future.